NCT07744191Not yet recruitingPhase 4
A Clinical Trial of Antiplatelets in Psoriasis
A Randomized, Double-blind, Placebo-controlled Crossover Trial of Antiplatelet Therapies in Psoriasis
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory/pro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 29 Jul 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 30 Sept 2031
- Lead sponsor
- NYU Langone Health
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT07744191
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 60
- From 1 Sept 2026 to the primary completion date, 30 Sept 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A prior history of a myocardial infarction, stroke/TIA, or occlusive peripheral arterial disease
- Chronic antiplatelet/anticoagulant use that is not able to be stopped at least 14 days prior to study enrollment
- Known active cancer receiving treatment
Other illness
- A history of severe bleeding or bleeding disorders
- Active gastrointestinal ulcer
- Active pathological bleeding.
- Chronic kidney disease (CrCl \< 30ml/min)
- Congestive heart failure
- Known hypersensitivity to or allergy to aspirin, clopidogrel, or any of the components of the study capsules
- History of aspirin-exacerbated respiratory disease or asthma induced by salicylates or NSAIDs
Lab values
- Uncontrolled hypertension resting systolic blood pressure \> 180 mm Hg or diabetes HbA1c \> 10%
- Anemia (hemoglobin \< 9 mg/dl) or thrombocytopenia (Platelet count \<75), or thrombocytosis (Platelet count \>600)
Other
- Pregnancy
- Currently breastfeeding
- Persons of childbearing potential unwilling to use acceptable contraception during the study
Who the study is looking for
- One of the following:
- A history of psoriasis as confirmed by a board-certified dermatologist OR
- A history of psoriatic arthritis as confirmed by a board-certified rheumatologist
- Age ≥ 18 \& \< 90 years
- Able and willing to provide written informed consent for the study
- English-speaking unless a translated informed consent form is approved
- No previous antiplatelet or anticoagulant use for 14 days prior to enrollment
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NYU Langone Health Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.